Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gohlke-Bärwolf, C.
Right arrow Articles by Zamorano, J. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gohlke-Bärwolf, C.
Right arrow Articles by Zamorano, J. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Hot topics in aortic stenosis

Proceedings of a satellite symposium organized by the Scientific Committee of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study in conjunction with the European Association of Echocardiography of the European Society of Cardiology, which was held during the meeting of the European Association of Echocardiography, EUROECHO, Lisbon, 6 December 2007

Christa Gohlke-Bärwolf1,* and Jose Luis Zamorano2

1 Bad Krozingen, Germany
2 Madrid, Spain

* Corresponding author. E-mail address: christa-gohlke@t-online.de

The first 10% of the full text of this article appears below.


   Introduction
 
This supplement of the European Heart Journal addresses important topics in aortic stenosis (AS), based on the presentations made at a satellite symposium of the annual congress EUROECHO 2007 in Lisbon.

Since the first descriptions of acquired calcific AS by Stokes in 1845 and by Mönckeberg in 1904, this disease has undergone a dramatic increase in incidence.

It is the third most common cardiovascular disease after hypertension and CAD and the most common native valve lesion, being present in 43% of all patients with valvular heart disease in the Euro Heart Survey on Valvular Heart disease.1 Aortic . . . [Full Text of this Article]


   Funding
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?